UNSPSC 51283922: Sulfathiourea

This classification denotes a sulfonamide anti-infective agent with the molecular formula C7H9N3O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MXF9G4I1V5, chemically known as urea, 1-sulfanilyl-2-thio- but generally known as sulfathiourea, which bears US NIH Compound Identifier 3000579. European Medicines Agency schedules Sulfathiourea in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10732MIG. The term SULFATHIOUREA is an International Non-Proprietary Name.

UNSPSC 51283922 Sulfathiourea is a Commodity code that nominally identifies a single chemical compound, but recent state and local procurement activity under this code shows little alignment with the code's name. The two most recent opportunities tagged to this code involve pharmaceutical procurement — one a completed award for antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) through a cooperative purchasing piggyback arrangement, and the other a request for Naloxone and drug deactivation systems for community health purposes. The mismatch between the code name and the actual goods being solicited suggests either data-entry error in the tagging or that state and local procurement systems are applying this code as a catch-all for certain pharmaceutical purchases rather than specifically for sulfathiourea compound. State and local health departments and county public health agencies are the issuing bodies represented in recent activity under this code.

The Illinois Department of Public Health issued the completed piggyback pharmaceutical award in August 2026 through the MMCAP Infuse consortium to Chartwell Rx LLC, totaling $2,999,999.11 over 12 months with two one-year renewal options. Seminole County, Florida solicited Naloxone and drug deactivation systems through an IFB with a July 26, 2023 deadline (note: this record contains a stale date that pre-dates the posting date, suggesting a data anomaly). Geographic activity appears concentrated in Florida and Illinois based on these two records. The absence of additional recent opportunities under this code, combined with the disconnect between the code's nominal scope and the actual pharmaceutical products being procured, suggests limited mainstream use of this code in state and local procurement. Businesses pursuing pharmaceutical supply contracts should verify coding with individual jurisdictions, as category assignment appears inconsistent across the sample.